Physician profile
Warren Hancock
NPI 1902196728
$1,719.27
in general payments reported to CMS, 2019-2025
18 companies · $36.91 in 2025
The $36.91 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $77.09 · 2021: $407 · 2022: $620 · 2023: $277 · 2024: $301 · 2025: $36.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $614.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $467.08 | 2021-2023 | |
| Novo Nordisk INC | $391.80 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $253.37 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Eisai INC. | $136.13 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $85.58 | 2022-2024 | Trintellix |
| Merck Sharp & Dohme LLC | $74.32 | 2022 | |
| Allergan, INC. | $46.48 | 2020 | |
| Antares Pharma, INC. | $43.57 | 2024 | Xyosted |
| Amarin Pharma, INC. | $33.30 | 2021-2022 | |
| Pfizer INC. | $28.23 | 2023-2024 | |
| Currax Pharmaceuticals LLC | $27.78 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.43 | 2022 | |
| Halozyme INC | $20.40 | 2023 | |
| Sumitomo Pharma America, INC. | $20.30 | 2025 | Gemtesa |
| Amgen INC. | $17.54 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $16.91 | 2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $15.14 | 2024 | Veozah |
| Biohaven Pharmaceuticals, INC. | $13.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Hancock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.